Latest advanced melanoma Stories
Statement from Tim Turnham, Executive Director, Melanoma Research Foundation WASHINGTON, Sept.
Decision Opens New Doors to Long-Awaited Combination Trials WASHINGTON, Aug. 17, 2011 /PRNewswire-USNewswire/ -- Melanoma patients who have long faced a bleak treatment landscape are gaining a new approach for treating the deadliest form of skin cancer.
Genetic analysis of the tumors from patients with advanced melanoma can clue researchers in to how well patients will respond to a therapy that targets the growth-promoting protein called BRAF, a researcher from the Perelman School of Medicine at the University of Pennsylvania will report on Monday, June 6 at the annual meeting of the American Society of Clinical Oncology.
The combination of two different chemotherapies and a previously approved treatment for kidney and liver cancers is not effective against advanced melanoma.
LONDON, May 18 /PRNewswire/ -- There are only two FDA/EMEA approved drugs currently available for treating advanced melanoma. The available drugs, however, are not completely effective and have adverse effects.
Patient advocacy group, research community and pharmaceutical companies join forces for new breakthroughs in treatment; clinical trials to begin in 2010 HILLSBOROUGH, N.J., Nov.
Researchers at the Moores UCSD Cancer Center are injecting a modified herpes virus into melanoma tumors, hoping to kill the cancer cells while also bolstering the body's immune defenses against the disease.
- Update from Advanced Breast Cancer and Melanoma Studies - Conference Call to be Hosted on Wednesday, June 3, 2009 at 11:00 am BRANFORD, Conn., May 28 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN) today announced plans for three data presentations from its ongoing clinical trials of CR011-vcMMAE, an antibody-drug conjugate that targets GPNMB, in patients with advanced breast cancer and melanoma at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO)...
- Updated Survival and Biomarker Data for Ipilimumab to be Presented - PRINCETON, N.J., April 29 /PRNewswire-FirstCall/ -- Medarex, Inc.
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.